First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

被引：0
|
作者：
Yanli Zhuang
Cesar Calderon
Stanley J Marciniak
Esther Bouman-Thio
Philippe Szapary
Tong-Yuan Yang
Allen Schantz
Hugh M. Davis
Honghui Zhou
Zhenhua Xu
机构：
[1] Janssen Research & Development,Biologics Clinical Pharmacology
[2] LLC,Compound Development
[3] Janssen Research & Development,Clinical Research
[4] LLC,Immunology
[5] DePuy Orthopaedics US Inc.,Quantitative Sciences
[6] Janssen Research & Development,undefined
[7] LLC,undefined
[8] Janssen Research & Development,undefined
[9] LLC,undefined
来源：
European Journal of Clinical Pharmacology | 2016年 / 72卷
关键词：
Anti-interleukin-23; Monoclonal antibody; Guselkumab; First-in-human; Pharmacokinetics; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1303 / 1310
页数：7
相关论文
共 50 条
  • [1] First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
    Zhuang, Yanli
    Calderon, Cesar
    Marciniak, Stanley J., Jr.
    Bouman-Thio, Esther
    Szapary, Philippe
    Yang, Tong-Yuan
    Schantz, Allen
    Davis, Hugh M.
    Zhou, Honghui
    Xu, Zhenhua
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (11) : 1303 - 1310
  • [2] Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
    Chiricozzi, Andrea
    Costanzo, Antonio
    Fargnoli, Maria Concetta
    Malagoli, Piergiorgio
    Piaserico, Stefano
    Amerio, Paolo
    Argenziano, Giuseppe
    Balato, Nicola
    Bardazzi, Federico
    Bianchi, Luca
    Carrera, Carlo Giovanni
    Conti, Andrea
    Dapavo, Paolo
    De Simone, Clara
    Loconsole, Francesco
    Lo Schiavo, Ada
    Malara, Giovanna
    Musumeci, Maria Letizia
    Parodi, Aurora
    Peris, Ketty
    Prignano, Francesca
    Rongioletti, Franco
    Talamonti, Marina
    Potenza, Concetta
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (01) : 3 - 16
  • [3] Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
    Andrea Chiricozzi
    Antonio Costanzo
    Maria Concetta Fargnoli
    Piergiorgio Malagoli
    Stefano Piaserico
    Paolo Amerio
    Giuseppe Argenziano
    Nicola Balato
    Federico Bardazzi
    Luca Bianchi
    Carlo Giovanni Carrera
    Andrea Conti
    Paolo Dapavo
    Clara De Simone
    Francesco Loconsole
    Ada Lo Schiavo
    Giovanna Malara
    Maria Letizia Musumeci
    Aurora Parodi
    Ketty Peris
    Francesca Prignano
    Franco Rongioletti
    Marina Talamonti
    Concetta Potenza
    European Journal of Dermatology, 2021, 31 : 3 - 16
  • [4] Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
    Sofen, Howard
    Smith, Stacy
    Matheson, Robert T.
    Leonardi, Craig L.
    Calderon, Cesar
    Brodmerkel, Carrie
    Li, Katherine
    Campbell, Kim
    Marciniak, Stanley J., Jr.
    Wasfi, Yasmine
    Wang, Yuhua
    Szapary, Philippe
    Krueger, James G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (04) : 1032 - 1040
  • [5] Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study
    Xu, Zhenhua
    Bouman-Thio, Esther
    Comisar, Craig
    Frederick, Bart
    Van Hartingsveldt, Bart
    Marini, Joseph C.
    Davis, Hugh M.
    Zhou, Honghui
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 270 - 281
  • [6] A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
    Gordon, Kenneth B.
    Langley, Richard G.
    Gottlieb, Alice B.
    Papp, Kim A.
    Krueger, Gerald G.
    Strober, Bruce E.
    Williams, David A.
    Gu, Yihua
    Valdes, Joaquin M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 (02) : 304 - 314
  • [7] Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis
    Ruiz-Villaverde, Ricardo
    Rodriguez-Fernandez-Freire, Lourdes
    Armario-Hita, Jose Carlos
    Perez-Gil, Amalia
    Chinchay, Fiorella Vasquez
    Galan-Gutierrez, Manuel
    DERMATOLOGIC THERAPY, 2022, 35 (10)
  • [8] First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers
    Rein-Hedin, Erik
    Sjoberg, Folke
    Waters, Susanna
    Sonesson, Clas
    Waters, Nicholas
    Huss, Fredrik
    Tedroff, Joakim
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (12): : 1485 - 1494
  • [9] Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
    He, Jinjie
    Du, Weijuan
    Yang, Haijing
    Wang, Jingjing
    Cai, Chenghang
    Ma, Qingyang
    Li, Nanyang
    Yu, Jicheng
    Wu, Xiaojie
    Wu, Jufang
    Chen, Yuancheng
    Cao, Guoying
    Zhang, Jing
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (07) : 669 - 675
  • [10] Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study
    Gargiulo, Luigi
    Ibba, Luciano
    Narcisi, Alessandra
    Giordano, Silvia
    Maronese, Carlo A.
    Martora, Fabrizio
    Repetto, Federica
    Paolino, Giovanni
    Balato, Anna
    Burlando, Martina
    Dapavo, Paolo
    Dini, Valentina
    Guarneri, Claudio
    Marzano, Angelo V.
    Megna, Matteo
    Mercuri, Santo R.
    Costanzo, Antonio
    Valenti, Mario
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2024, 14 (04):
12345